Related Experiment Video

Updated: May 19, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Emerging role of multikinase inhibitors for refractory thyroid cancer

Cesar A Perez1, Belisario A Arango, Michel Velez

  • 1University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA.

Biologics : Targets & Therapy
|August 21, 2012
PubMed

Insights

Multikinase inhibitors are revolutionizing thyroid cancer treatment. These novel agents effectively manage advanced, refractory thyroid cancer, improving patient survival and response duration.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer incidence is rising, making it the most common endocrine malignancy.
  • Refractory thyroid cancer requires novel systemic therapies due to prevalent driver mutations and pathway overexpression.

Purpose of the Study:

  • To discuss the molecular rationale and clinical efficacy of multikinase inhibitors for advanced thyroid cancer.
  • To highlight the paradigm shift in treating differentiated and medullary thyroid cancer.

Main Methods:

  • Review of clinical studies involving multikinase inhibitors in thyroid cancer.
  • Analysis of the molecular pathways targeted by these novel agents.

Main Results:

  • Multikinase inhibitors demonstrate significant efficacy in advanced, iodine-refractory thyroid cancer.
  • These agents induce prolonged responses and improve survival by simultaneously inhibiting key pathways like RET, MAPK, and angiogenesis.
  • Promising clinical activity observed in both differentiated and medullary thyroid cancer subtypes.

Conclusions:

  • Multikinase inhibitors represent a new era in thyroid cancer management, offering effective systemic therapy.
  • The targeted inhibition of multiple molecular pathways explains their success in controlling malignancy progression.
  • Vandetanib approval marks a significant advancement in medullary thyroid cancer treatment.
Keywords:
axitinibcabozantiniblenvatinibmitogen-activated protein kinase (MAPK)motesanibpazopanibthyroid cancervandetanibvascular endothelial growth factor receptor-2 (VEGFR2)

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: